Noticias de Eulerpool Interpace Biosciences

Interpace Biosciences Noticias de Acciones

Interpace Biosciences es observado por muchos periodistas e inversores en todo el mundo. Aquí recopilamos las noticias más recientes de Interpace Biosciences.

• 24 de abril ·

  Yahoo
  Effective May 2, 2025, Interpace Diagnostics® Will No Longer Accept Specimens for PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk
• 10 de enero ·

  Yahoo
  Effective 02/07/2025, Interpace Diagnostics® to No Longer Offer PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk
• 4 de noviembre ·

  Yahoo
  Interpace Biosciences Announces Record Third Quarter 2024 Financial and Business Results
• 15 de octubre ·

  Yahoo
  Interpace Biosciences Announces Capital Restructuring of Its Preferred Stock as a First Step Toward Seeking an Uplisting of Its Common Stock to Nasdaq
• 15 de octubre ·

  TipRanks
  Interpace Diagnostics Strategic Stock Exchange for Nasdaq Uplisting
• 2 de agosto ·

  Seeking Alpha
  Interpace Biosciences GAAP EPS of $0.48, revenue of $12M
• 1 de agosto ·

  Yahoo
  Interpace Biosciences Announces Record Second Quarter 2024 Financial and Business Results
• 29 de julio ·

  Yahoo
  Interpace Diagnostics® Announces Undefined Extension of Medicare Coverage for PancraGEN®, a Molecular Diagnostic Test That Assesses Cancer Risk of Pancreatic Cysts
• 29 de julio ·

  Thefly.com
  Interpace Biosciences announces extension of Medicare coverage for PancraGEN